1st Qtrly 16-17 2nd Qtrly 16-17 3rd Qtrly 16-17 4th Qtrly 16-17 30TH ANNUAL REPORT 2015-2016
1st Qtrly 15-16 2nd Qtrly 15-16 3rd Qtrly 15-16 4th Qtrly 15-16 29TH ANNUAL REPORT 2014-2015
1st Qtrly 14-15 2nd Qtrly 14-15 3rd Qtrly 14-15 4th Qtrly 14-15 28TH ANNUAL REPORT 2013-2014
1st Qtrly 13-14 2nd Qtrly 13-14 3rd Qtrly 13-14 4th Qtrly 13-14 27TH ANNUAL REPORT 2012-2013
1st Qtrly 12-13 2nd Qtrly 12-13 3rd Qtrly 12-13 4th Qtrly 12-13 26TH ANNUAL REPORT 2011-2012
1st Qtrly 11-12 2nd Qtrly 11-12 3rd Qtrly 11-12 4th Qtrly 11-12 25TH ANNUAL REPORT 2010-2011

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED RESULTS FOR THE QUARTER ENDED : 30TH SEPTEMBER 2013.

  (Rupees in '000')
S. No. Particulars
Un -audited
Un-audited
Audited
Quarter Ended Half Year Ended Year Ended
30.Sep.13 30.Jun.13 30.Sep.12 30.Sep.13 30.Sep.12 31.Mar.13
PART-l (a)Income from Operation            
1 Gross Sales
19,712
20,712
19,157
40,424
42,410
76,818
  less Excise Duty
1,261
1,398
1,264
2,659
2,811
5,282
  Net Sales/Income From Operation
18,451
19,314
17,893
37,765
39,599
71,536
  (b) Other Operating Income - - - - - 323
  Total Income from Operation
18,451
19,314
17,893
37,765
39,599
71,859
2
Expenditure
           
  (a)
Consumption of Materials
5,154 6,601 7,088 11,755 13,072 21,402
  (b)
Purchase of Goods Traded
1,344
1,777
1,504
3,121
3,374
5,460
  (c) (Increase)/Decrease in stock in trade
1,679
15
(2,224)
1,694
165
1,702
  (d) Staff Cost
6,614
6,212
6,592
12,826
13,473
25,748
  (e) Depreciation
657
655
653
1,312
1,306
2,619
  (f) Other Expenses
2,892
3,397
3,509
6,289
6,621
12,083
  Total Expenditure
18,340
18,657
17,122
36,997
38,011
69,014
3 Profit/(Loss) from Operation Before Other Income ( 1-2)
111
657
771
768
1,588
2,845
4 Other Income (Loss)
299
51
248
350
454
775
5 Profit /Loss before Interest & Exceptional items (3+4)
410
708
1,019
1,118
2,042
3,620
6 Interest
291
405
542
696
1,079
2,021
7 Profit /Loss after Interest but before exceptional items (5-6)
119
303
477
422
963
1,599
8 Exceptional items - -   - - -
9 Profit /Loss before Tax ( 7-8)
119
303
477
422
963
1,599
10 Tax Expenses ( Provision for Taxation ) Current tax - - - - - 297
  Deffered tax - - - - - 504
11 Net Profit/Loss after Tax (9-10)
119
303
477
422
963
798
12 Paid up Equity Share Capital ( Face Value 10/- Per Share ) [Net of allotment money in arrears] 354,35 354,35 354,35 354,35 354,35 354,35
13

Reserves Excluding Revaluation Reserves

- - - - - 8,428
14

Earning per share (EPS) before extraordinary item( not Annualised)

-

 

- - - - -
  i) Basic & Diluted - - - - - 0.17
  ii) Diluted - - - - - -
 
PART-ll PARTICULARS OF SHAREHOLDING            
1 Public shareholding            
  i Number of Shares
2,894,901
2,904,901
2,904,901
2,894,901
2,904,901
2,904,901
  ii Percentage of shareholding
63.33%
63.55%
63.55%
63.33%
63.55%
63.55%
2 Promoters and promoter group Shareholding            
  a) Pledged/Encumbered            
  i Number of shares - - - - - -
  ii Percentage of shares (as a % of the total shareholding of promoter and promoter group) - - - - - -
  iii Percentage of shares (as a% of the total share capital of the company) - - - - - -
  b) Non-encumbered            
  - Number of Shares
1,676,099
1,666,099
1,666,099
1,676,099
1,666,099
1,666,099
  - Percentage of shares (as a% of the total shareholding of promoter and promoter group)
36.67%
36.45%
36.45%
36.67%
36.45%
36.45%
  Percentage of shares (as a % of the total share capital of the company)
100%
100%
100%
100%
100%
100%

 

B. INVESTORS COMPLAINTS 3 Months ended 30.09.2013
  Pending at Begining of the Quarter  NIL
  Received During the Quarter NIL
  Disposed of During the Quarter NIL
  Remaining at the end of the Quarter NIL

 

STATEMENT OF ASSETS AND LIABILITIES
(Rupees in '000')
Particulars As at 30.09.2013 As at 31.03.2013
(Un-Audited) (Audited)
A   EQUITY AND LIABILITIES  
1   SHARE HOLDERS FUND  
  a)  Share Capital 35,435 35,435
  b)   Reserves and Surplus
27,571
27,149
  Total
63,006
62,584
2   NON CURRENT LIABILITIES
  a) Long term borrowing 
20,578
22,554
  b) Deffered tax liability(net) 3,604 3,604
  c) Other long term liability 155 147
  d) Long term Provision - -
  Total
24,337
26,305
3   CURRENT LIABILITIES  
  a) Short term borrowing  - -
  b) Trade payable 7,110 4,013
  c) Other current liabilities 6,423 5,652
  d) Short term provision - -
  Total 13,533 9,665
       
   
Total ( 1+2+3)
100,876 98,554
 
B   ASSETS  
1   NON CURRENT ASSETS  
  a) Fixed Assets
38,476
39,761
  b) Non current investments
3,159
3,159
  c) Long term loans and advances  13,543 13,543
  d) Other Non current assets 0 599
  Total
55,178
57,062
2   CURRENT ASSETS
  a) Inventories
17,395
18,606
  b) Trade receivable
16,472
12,717
  c) Cash and cash equivalents
10,331
9,384
  d) Short term loans and advances
1,500
785
    Sub-Total of  Current Assets
45,698
41,492
   
   
Total ( 1+2 )
100,876
98,554

 

NOTES :-

  1. The above financial results have been taken on record at a meeting of Board of Directors held on 31-10-2013
  2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
  3. Previous period figures have been regrouped wherever required.

 

  For and on behalf of the Board
  M/s. COLINZ LABORATORIES LIMITED
   
Mumbai Dr. L. S. Mani
31.10.2013 Chairman & Managing Director.

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in